InvestorsHub Logo
Followers 32
Posts 2552
Boards Moderated 0
Alias Born 07/16/2006

Re: enemem post# 19745

Friday, 08/08/2008 1:49:39 PM

Friday, August 08, 2008 1:49:39 PM

Post# of 52043
One can make an argument for Ampakines as cognitive enhancers in mild AD--but then again, you can make an argument for nicotinics, 5HT-6, PDE4, mGluR approaches, and more in the same vein. Highly competitive--it'd be a perfectly reasonable secondary target for a low-impact, but that's not the real key to a huge AD drug. Altering disease course is where they have to head. And I have yet to see a good case made for low-impacts as neurotrophics.

NeuroInvestment
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent RSPI News